10-Q: CVS Health Reports Q1 2024 Results: Revenue Up, Earnings Down Amidst Increased Healthcare Costs

• CVS Health's total revenues for the first quarter of 2024 increased by 3.7% to $88.4 billion, compared to $85.3 billion in the same period last year.
• The revenue growth was driven by increases in premiums and services, while product revenues decreased.
• Net income attributable to CVS Health decreased significantly to $1.1 billion, compared to $2.1 billion in the first quarter of 2023.
• This decline in net income was primarily due to increased healthcare costs, particularly in the Health Care Benefits segment, and other factors such as pharmacy client price improvements and the loss of a large client in the Health Services segment.
• Operating income decreased by 34.1% to $2.3 billion, compared to $3.4 billion in the prior year.
• The company's effective income tax rate increased to 28.9% from 25.6% in the prior year.
• The Health Care Benefits segment saw a significant increase in its medical benefit ratio (MBR) to 90.4% from 84.6% due to higher Medicare utilization and other factors.
• The Health Services segment experienced a revenue decrease of 9.7%, while the Pharmacy & Consumer Wellness segment saw a revenue increase of 2.9%.

Score: 4

Explanation: The document presents a mixed picture with revenue growth offset by significant declines in profitability and increased healthcare costs. The outlook is cautious, with several risks and uncertainties highlighted. Overall, the sentiment is negative from an investment perspective.

• Total revenues increased by 3.7% year-over-year, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
• The Pharmacy & Consumer Wellness segment saw a 3.2% increase in prescriptions filled.
• The company continues to see growth in its new Cordavis, Oak Street Health and Signify Health businesses.
• Operating expenses as a percentage of total revenues decreased in the Health Care Benefits segment, reflecting improved fixed cost leverage due to membership growth.

• Net income attributable to CVS Health decreased by 47.9% year-over-year.
• Operating income decreased by 34.1% year-over-year.
• The Health Care Benefits segment experienced a significant increase in its medical benefit ratio (MBR) due to higher Medicare utilization and the unfavorable impact of the company's 2024 Medicare Advantage star ratings.
• The Health Services segment experienced a revenue decrease of 9.7% due to the loss of a large client and continued pharmacy client price improvements.
• The company's effective income tax rate increased to 28.9% from 25.6% in the prior year.

• Elevated Medicare utilization is expected to continue to pressure the Health Care Benefits segment and its health care delivery assets.
• The cyberattack on Change Healthcare significantly impaired visibility across the health insurance industry, resulting in delayed claims processing.
• Ongoing GLP-1 supply constraints could pressure the Pharmacy Services business.
• Competitive pressures in the retail pharmacy industry are increasing.
• Consumer spend management and a decline in consumer discretionary spending could drive lower front store sales.
• The company is exposed to changes in government policy and funding with respect to Medicare programs.
• Legislation and regulations seeking to regulate PBM activities could adversely affect the company's ability to conduct business on commercially reasonable terms.

The company expects continued elevated healthcare utilization, particularly in Medicare Advantage programs, to pressure its Health Care Benefits segment and health care delivery assets for the remainder of the year. They also anticipate growth in their new Cordavis, Oak Street Health and Signify Health businesses.

• The company is creating new sources of value through its integrated model allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.
• The company expects benefits from ongoing enterprise-wide cost savings initiatives and investments in efficiencies, which aim to reduce the company's operating cost structure in a way that improves the consumer experience and is sustainable.

The results reflect broader industry trends of increased healthcare utilization and cost pressures, particularly in Medicare Advantage programs. The company is also facing increasing competition in the retail pharmacy industry and regulatory changes impacting PBM activities.

• CVS Health's MBR increase to 90.4% is higher than some of its competitors, indicating higher healthcare costs relative to premiums.
• UnitedHealth Group, a major competitor, reported a medical care ratio of 84.3% in its Q1 2024 results, which is lower than CVS Health's MBR.
• Humana, another competitor, reported a benefit ratio of 87.9% in its Q1 2024 results, also lower than CVS Health's MBR.
• The decline in CVS Health's net income is more pronounced than some of its competitors, suggesting specific challenges in managing costs and pricing.
• CVS Health's revenue growth of 3.7% is comparable to some of its competitors, but the decline in net income is a significant point of difference.

• Shareholders are impacted by the decrease in net income and operating income.
• Employees may be affected by cost savings initiatives and changes in business operations.
• Customers may experience changes in service delivery and pricing.
• Suppliers may be impacted by changes in purchasing and contracting practices.
• Creditors may be affected by changes in the company's financial performance and debt levels.

• The company expects to continue to focus on cost savings initiatives and investments in efficiencies.
• The company will continue to monitor and manage healthcare utilization, particularly in Medicare Advantage programs.
• The company will continue to grow its new Cordavis, Oak Street Health and Signify Health businesses.

• The company is involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims.
• These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, the U.S. Department of Justice (the DOJ), state Attorneys General, the U.S. Drug Enforcement Administration (the DEA), the U.S. Federal Trade Commission (the FTC) and other governmental authorities.
• The company is named as a defendant in a number of lawsuits that allege that the company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.
• The company is facing multiple lawsuits and investigations concerning its PBM practices, including drug pricing and rebate arrangements with drug manufacturers.
• The company is defending itself against claims related to the dispensing of opioid medications and has agreed to a formal settlement agreement with a leadership group of a number of state Attorneys General and the Plaintiffs Executive Committee.
• The company is also subject to a number of investigations concerning its prescription processing practices, including related to billing government payors for prescriptions.
• The company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers.
• The company has received CIDs from the Civil Division of the DOJ in connection with investigations of the company's identification and/or submission of diagnosis codes related to risk adjustment payments under Parts C and D of the Medicare program.
• The company is defending itself against multiple class action complaints, as well as a derivative complaint, that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the company's LTC business unit.

• The company has an equity method investment in SureScripts, LLC, and expensed fees for the use of this network of $6 million in the three months ended March 31, 2024.

• May 2, 2023: The Company acquired 100% of the outstanding shares and voting interest of Oak Street Health.
• March 25, 2024: The Company entered into a 364-day $3.0 billion term loan credit agreement.
• March 31, 2024: End of the first quarter of 2024.
• April 1, 2024: CMS issued its final notice detailing final 2025 Medicare Advantage payment rates.
• April 24, 2024: The registrant had 1,255,372,972 shares of common stock issued and outstanding.
• May 1, 2024: Date of the report.